FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Tecfidera (Dimethyl Fumarate) in Children with MS: A Dual-Center Study: STUDY






















Image Source: MSVIEWSANDRELATEDNEWS


Abstract

Background:
First-line injectable therapies for multiple sclerosis (MS) in children may be ineffective or not well-tolerated. There is therefore an urgent need to explore oral medications for pediatric MS. We review our dual-center experience with oral dimethyl fumarate (DMF).

Methods:
Retrospective chart review of children with MS < 18 years treated with DMF at Yale University and the University of Colorado. Clinical, demographic, and MRI parameters were analyzed.

Results:
We identified 13 children treated with oral DMF for a median of 15.0 months (range 1-25). DMF was utilized first-line in five children (38%). Ten children (77%) tolerated dose escalation to usual adult dose of 240 mg BID. Nine children had > 12 months of follow-up on treatment. Eight of nine (89%) displayed either stabilized or reduced relapse rates and disability scores on treatment. Nine children had brain MR imaging performed after > 12 months of therapy. New T2 lesions were observed in three children (33%), one of whom had been non-adherent to treatment. Common side effects included facial flushing (8/13, 62%), gastrointestinal discomfort (7/13, 54%), rash (3/13, 23%), and malaise (2/13, 15%). Three children (23%) discontinued treatment due to side effects. No patients displayed laboratory abnormalities including lymphopenia or abnormal liver transaminases. There were no reported infections.

Conclusions:
Oral DMF appears to be safe and generally well-tolerated in children with MS. Formal clinical trials to evaluate efficacy are ongoing.

Story Source: The above story is based on materials provided by PEDIATRICNEUROLOGY
Note: Materials may be edited for content and length

Labels: ,



Go to Newer News Go to Older News